Lalande Sophie, Snyder Eric M, Olson Thomas P, Hulsebus Minelle L, Orban Marek, Somers Virend K, Johnson Bruce D, Frantz Robert P
Division of Cardiovascular Diseases, Mayo Clinic, College of Medicine, Rochester, MN 55905, USA.
Eur J Appl Physiol. 2009 Jul;106(4):509-15. doi: 10.1007/s00421-009-1042-5. Epub 2009 Apr 1.
The reduced arterial oxygen tension at high altitude impairs the ability to work. Acetazolamide improves arterial oxygen saturation (SaO(2)) by increasing ventilation but is associated with an increased work and cost of breathing. Depending on the settings, sildenafil can also increases SaO(2) possibly through a reduction in pulmonary hypertension and interstitial edema, which could improve ventilation-perfusion matching. The objective of this study is to determine the effects of acetazolamide and sildenafil on ventilatory control and breathing efficiency (V(E)/VCO(2)) during submaximal steady-state hypoxic exercise in healthy individuals. Following 18 h of hypoxic exposure in an altitude tent at an oxygen concentration of 12.5% (simulated altitude of 4,300 m), 15 participants performed 10 min of hypoxic exercise on a stationary bicycle at 40% of their sea level peak oxygen uptake (VO(2)) while randomly receiving sildenafil 40 mg (SIL), acetazolamide 125 mg (ACZ) or a placebo (PLA). There was no difference in VO(2) during exercise between conditions while SaO(2) was greater with acetazolamide compared to both placebo and sildenafil. Acetazolamide increased ventilation (PLA 49.0 +/- 3.2, SIL 47.7 +/- 3.1, ACZ 52.1 +/- 3.0 l/min) and reduced end-tidal CO(2) (P(ET)CO(2)) (PLA 32.1 +/- 0.8, SIL 32.8 +/- 0.9, ACZ 29.2 +/- 0.7 mmHg) compared to placebo and sildenafil. Breathing was less efficient with acetazolamide (increased V(E)/VCO(2)) in comparison to placebo and sildenafil (PLA 41.5 +/- 1.0, SIL 40.4 +/- 1.3, ACZ 45.4 +/- 1.0) while sildenafil did not change V(E)/VCO(2) during hypoxic exercise. In conclusion, acetazolamide increased ventilation and reduced breathing efficiency while sildenafil did not affect breathing efficiency despite a trend toward a blunted ventilatory response, possibly due to a reduction in pulmonary hypertension and/or ventilatory drive, during submaximal hypoxic exercise in healthy individuals.
高海拔地区动脉血氧分压降低会损害工作能力。乙酰唑胺通过增加通气来提高动脉血氧饱和度(SaO₂),但会增加呼吸做功和成本。根据具体情况,西地那非也可能通过降低肺动脉高压和间质性水肿来增加SaO₂,从而改善通气-灌注匹配。本研究的目的是确定乙酰唑胺和西地那非对健康个体在次最大稳态低氧运动期间通气控制和呼吸效率(V(E)/VCO₂)的影响。在海拔模拟帐篷中以12.5%的氧浓度(模拟海拔4300米)进行18小时低氧暴露后,15名参与者在固定自行车上以其海平面峰值摄氧量(VO₂)的40%进行10分钟的低氧运动,同时随机接受40毫克西地那非(SIL)、125毫克乙酰唑胺(ACZ)或安慰剂(PLA)。各条件下运动期间的VO₂无差异,而与安慰剂和西地那非相比,乙酰唑胺组的SaO₂更高。与安慰剂和西地那非相比,乙酰唑胺增加了通气量(PLA组49.0±3.2、SIL组47.7±3.1、ACZ组52.1±3.0升/分钟)并降低了呼气末二氧化碳(P(ET)CO₂)(PLA组32.1±0.8、SIL组32.8±0.9、ACZ组29.2±0.7毫米汞柱)。与安慰剂和西地那非相比,乙酰唑胺组的呼吸效率较低(V(E)/VCO₂增加)(PLA组41.5±1.0、SIL组40.4±1.3、ACZ组45.4±1.0),而西地那非在低氧运动期间未改变V(E)/VCO₂。总之,在健康个体的次最大低氧运动期间,乙酰唑胺增加了通气量并降低了呼吸效率,而西地那非尽管有通气反应减弱的趋势,但并未影响呼吸效率,这可能是由于肺动脉高压和/或通气驱动力降低所致。